The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $430.50, demonstrating a -1.06% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.

I’m upgrading Vertex to a "Neutral" rating after its sharp stock decline corrected prior valuation concerns, but risks remain substantial. Vertex balances mid-teens revenue growth with high-teens ...

Vertex Pharmaceuticals VRTX is scheduled to report its first-quarter 2026 results on May 4, after market close. The Zacks ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was among Jim Cramer’s recent stock calls on Mad Money. During the ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of a biotech success story. The company has developed strength in a specialty area and, thanks to that, has delivered a track record of revenue ...

Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the ...

View Vertex, Inc. Class A VERX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...